Philips and Bruker BioSpin sign memorandum of understanding to bring new imaging technology to the preclinical market
Montreal, Canada – At the 2009 World Molecular Imaging Congress (WMIC) in Montreal, Royal Philips Electronics (NYSE: PHG, AEX: PHI) and Bruker BioSpin, a division of Bruker Corporation (NASDAQ: BRKR), today announced that they have signed a memorandum of understanding (MOU) for the development of Magnetic Particle Imaging (MPI) scanners, a new imaging technology, for the preclinical market. The partnership would unite Philips’ strength in medical imaging and Bruker BioSpin’s leadership in analytical magnetic resonance instruments and preclinical Magnetic Resonance Imaging (MRI).
Under the terms of the MOU, Bruker BioSpin intends to develop and manufacture the preclinical MPI scanner at its facilities in Ettlingen, Germany. Both parties intend to co-market the resulting solution. Preclinical imaging has emerged as a powerful tool in disease studies, translational research and drug discovery. Philips and Bruker BioSpin believe that the addition of MPI as a complementary preclinical imaging technique has great potential to help researchers gain new insights in disease processes at the organ, cellular and molecular level.
MPI is a new medical imaging technology developed by scientists at Philips. It uses the magnetic properties of iron-oxide nanoparticles to produce three-dimensional images of the concentration of nanoparticles injected into the bloodstream. The potential of the technology for medical and industrial research and, ultimately, patient care, was demonstrated in a publication which appeared in the March issue of Physics in Medicine and Biology in 2009 (Volume 54, issue 5). It was shown that MPI technology can be used to produce real-time images that accurately capture the activity in the cardiovascular system of a mouse.
“We are very pleased about this collaboration with Philips on this exciting technology. Magnetic Particle Imaging is expected to allow scientists to explore an extensive range of new imaging capabilities and applications in preclinical research, ” said Wulf-Ingo Jung, Managing Director of Bruker BioSpin MRI GmbH. “The highly sensitive visualization of functional characteristics in vivo at high temporal resolution bears great potential for small animal imaging, especially when combined with high spatial resolution morphological MRI.”
“Through its combined speed, resolution and sensitivity, our Magnetic Particle Imaging technology has great potential for the diagnosis, therapy planning and therapy response assessment for major diseases such as heart disease and cancer,” said Diego Olego, Senior Vice President and Chief Technology Officer of Philips Healthcare. “We are excited about the agreement with Bruker BioSpin as it will lead to the availability of MPI scanners for preclinical research studies, which is a prerequisite for establishing the value of this promising new technology for patient care.”
A key success factor for the effective translation of new imaging concepts into practice are partnerships with leading academic medical institutions, industrial partners and governments. Bringing together such partnerships is one of the underlying principles behind Philips’ policy of open innovation. The results obtained in the MAGIC (Magnetic Particle Imaging for Cardio-Vascular Applications) research project conducted at the Philips Research Laboratories in Hamburg (Germany), have significantly contributed to the development of MPI. The project was funded by the German Federal Ministry of Education and Research under grant Number 13N9079 as part of the NanoForLife Framework Program. The project was started in 2006 and will finish by the end of this year.
About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified Health and Well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of “sense and simplicity”. Headquartered in the Netherlands, Philips employs approximately 116,000 employees in more than 60 countries worldwide. With sales of EUR 26 billion in 2008, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.
About Bruker BioSpin
For more information about Bruker BioSpin and Bruker Corporation, please visit www.bruker-biospin.com and www.bruker.com.
Bruker Cautionary Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.
WebWireID104371
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.